1. Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris.
- Author
-
Ishii H, Kobayashi M, Kurebayashi N, Yoshikawa D, Suzuki S, Ichimiya S, Kanashiro M, Sone T, Tsuboi H, Amano T, Uetani T, Harada K, Marui N, and Murohara T
- Subjects
- Aged, Aged, 80 and over, Angiotensin II Type 1 Receptor Blockers adverse effects, Combined Modality Therapy, Disease Progression, Double-Blind Method, Female, Humans, Hypertension complications, Imidazoles adverse effects, Long-Term Care, Male, Middle Aged, Tetrazoles adverse effects, Valine adverse effects, Valine therapeutic use, Valsartan, Angina Pectoris diagnostic imaging, Angina Pectoris therapy, Angioplasty, Balloon, Coronary, Angiotensin II Type 1 Receptor Blockers therapeutic use, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Image Interpretation, Computer-Assisted, Imidazoles therapeutic use, Tetrazoles therapeutic use, Ultrasonography, Interventional, Valine analogs & derivatives
- Abstract
Coronary plaques can be reduced by some medications. The aim of this study was to compare the effects of 2 angiotensin II receptor blockers (olmesartan at 20 mg/day or valsartan at 80 mg/day) on coronary plaque by coronary intravascular ultrasound. One hundred hypertensive patients with stable angina pectoris who underwent elective percutaneous coronary intervention were randomly selected to receive 1 of the 2 angiotensin II receptor blockers after coronary intervention. Nontarget coronary lesions with mild to moderate stenosis were measured by volumetric intravascular ultrasound at baseline and after 6 months. After 6 months, both the olmesartan and the valsartan groups showed significant reduction of the examined coronary plaque volume (46.2 ± 24.1 mm³ at baseline vs 41.6 ± 21.1 mm³ at 6 months: 4.7% decrease, p = 0.0002; and 47.2 ± 32.7 mm³ at baseline vs 42.5 ± 30.2 mm³ at 6 months: 4.8% decrease, p = 0.002, respectively). There was no statistically significant difference of plaque regression between the 2 groups (p = 0.96). In conclusion, there was a significant decrease from baseline in the coronary plaque volume in patients with stable angina pectoris who received olmesartan or valsartan for 6 months. In addition, there was no significant difference in the reduction of plaque volume achieved by these 2 medications., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF